Babraham Investor Conference

Content Gallery

Taylor Vinters is an international law firm supporting the businesses which drive the innovation economy, and the entrepreneurs and private wealth that underpin them.

Website

Handelsbanken is a full-service bank with a decentralised way of working, a strong local presence due to a nationwide network of over 200 branches and a long-term approach to customer relations.

Website

Keynote Speaker: Daniel Mahony PhD

Polar Capital is a specialist, investment-led, active fund manager who strive to be investment leaders.

Company Bio
Website
LinkedIn

Keynote Speaker: Martin Murphy PhD

Syncona, is a leading FTSE 250 healthcare company focused on founding, building and funding a portfolio of global leaders in life sciences.

Company Bio
Website
LinkedIn
Twitter

Critical Pressure is a pre-clinical stage company with a novel vasopressor asset that targets the pathophysiology of septic shock and post coronary artery bypass vasoplegia.

Company Bio
Website
Twitter
Video

Kalium Health is working to help millions of people living with kidney or heart disease to manage their health at home.

Comapny Bio
Website
Twitter
LinkedIn
Video

New Path Molecular is a University of Cambridge spin-out translating the ground-breaking work of Professor S. V. Ley in machine assisted synthesis of functional molecules into the discovery of small proteins to treat cancer and other diseases. New Path is developing molecules which bind to the abnormal lipids in cancer cell membranes and vasculature to target solid tumours.

Company Bio
Website
LinkedIn
Video

Shift Bioscience are a self-originated company looking at health-span extension. The mission of Shift Bioscience is to enable curative drugs against age-linked diseases. We are raising new funds to ready our initial product (SB200) for licensing to Pharma, and to build a platform for the next generation of health-span extension therapeutics.

Company Bio
Website
PDF
Twitter
LinkedIn

At Alchemab Therapeutics, we are harnessing the power of our immune system to cure disease.  We turn drug discovery on its head by using nature’s most effective search engine: adaptive immunity.

Head of Departments

  • Alex Leech, MBA – CEO
  • Dr Jane Osbourn, OBE, PhD – CSO
  • Dr Olivia Cavlan, MD – Head of Business & Operations
  • Dr Ralph Minter, PhD, FRSB – Head of Research

Dr Jane Osbourn is presenting for Alchemab at the Babraham Investor Conference.

Company Bio
Website
Twitter
LinkedIn

A new novel technology platform for the production of low-cost glycoconjugate vaccines against several bacteria affecting poultry, pigs and ruminants.

Company Bio
Website
Twitter

bit.bio are a spin out from Cambridge University specialising in human synthetic biology. Having access to unlimited supplies of human cells is a game changer – it will transform the biotech and medicine research landscape and enable a new generation of engineered cell therapies.

Company Bio
Website
Twitter
LinkedIn

ConcR is an emerging predictive software platform built to combat cancer, aiming to reduce the uncertainty involved in treating cancer and develop novel cancer therapeutics.

Compnay Bio
Website
Accelerate – current cohort
LinkedIn

Maxion Therapeutics’ Knotbody technology has the potential to transform the treatment of ion channel driven disease.

Compnay Bio
Website
Twitter
LinkedIn

NRG  Therapeutics is a drug discovery company focused on therapeutic  approaches that will restore mitochondrial function and slow or halt the  progression of neurodegenerative diseases.

Company Bio
Website
LinkedIn

Of all the children who are deaf across the world fewer than 10% are wearing a hearing aid of any kind. Paediatric HealthTech in collaboration with Raspberry Pi has developed an affordable solution for the most common type of hearing loss in childhood affecting the middle ear.

Company Bio
Website
PDF
Twitter
Contact

Stroma Biosciences is a pre-clinical target and drug discovery venture focused on the tumour microenvironment.

Company Bio
Twitter

TRx Biosciences is a private start up and biotech spin out. TRx is a rapidly growing platform development company with an already impressive pipeline and collaborations. Its proven technology underpins a tremendous value growth potential in TRx and an early exit for investors is a key focus of the team. TRx are looking to raise awareness of TRx to Pharma, Collaborators and Early stage investors, and are looking for funding of up to £500K from an Angel VC or Private investor.

If you have any questions or would like to get in contact with any of the above companies, please contact register@babraham.co.uk with your details.